OSD
Safely scaling high potency API manufacturing: containment, strategy and commercial readiness in modern pharma
Readers will learn:
- How HPAPIs are defined and managed within Occupational Exposure Limit (OEL) and Occupational Exposure Band (OEB) frameworks
- Common sources of risk in high potency manufacturing and how integrated containment controls addresses them
- Practical design and operational strategies for safe and compliant HPAPI production
- How technical transfer and scale up are managed for high potency products
- The role of digitalisation, automation and sustainability in next generation HPAPI operations
- Key design considerations during HPAPI scale-up and tech transfer processes
Manufacturing High Potency Active Pharmaceutical Ingredients (HPAPIs) requires precise handling, robust containment and disciplined process control. As more therapies rely on highly active compounds, particularly in oncology and immunology, the ability to manage these materials safely and efficiently has become a defining
capability for pharmaceutical manufacturers and CDMOs.
This whitepaper outlines the key considerations in HPAPI manufacturing from how potency is defined and classified to the practical challenges of process design, containment and scale up. It explains how an integrated containment strategy combining equipment design, facility layout and procedural controls supports both operator safety and regulatory compliance.
The paper also explores how advances in automation, digitalisation and sustainability are shaping the future of high potency manufacturing and helping organisations reduce risk and improve efficiency while maintaining the highest standards of quality and safety